Concepts (273)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress Disorders, Post-Traumatic | 49 | 2023 | 389 | 10.090 |
Why?
|
| Sleep | 22 | 2022 | 152 | 5.370 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 12 | 2022 | 63 | 5.070 |
Why?
|
| Sleep, REM | 9 | 2017 | 11 | 2.070 |
Why?
|
| Autonomic Nervous System | 5 | 2019 | 33 | 2.000 |
Why?
|
| Fear | 7 | 2022 | 249 | 1.710 |
Why?
|
| Polysomnography | 13 | 2019 | 42 | 1.600 |
Why?
|
| Urban Population | 6 | 2016 | 333 | 1.570 |
Why?
|
| Veterans | 6 | 2018 | 122 | 1.440 |
Why?
|
| Heart Rate | 6 | 2019 | 253 | 1.370 |
Why?
|
| Wounds and Injuries | 6 | 2015 | 161 | 1.250 |
Why?
|
| Young Adult | 21 | 2022 | 4268 | 1.250 |
Why?
|
| Circadian Rhythm | 4 | 2016 | 225 | 1.220 |
Why?
|
| Humans | 74 | 2023 | 37093 | 1.150 |
Why?
|
| Adult | 43 | 2022 | 11712 | 1.060 |
Why?
|
| Resilience, Psychological | 2 | 2016 | 66 | 0.980 |
Why?
|
| Stress, Psychological | 5 | 2018 | 583 | 0.940 |
Why?
|
| Male | 49 | 2023 | 20025 | 0.930 |
Why?
|
| Female | 47 | 2023 | 20969 | 0.900 |
Why?
|
| Adolescent | 20 | 2022 | 5363 | 0.830 |
Why?
|
| Polymorphism, Genetic | 2 | 2016 | 191 | 0.830 |
Why?
|
| Psychiatric Status Rating Scales | 6 | 2018 | 253 | 0.760 |
Why?
|
| Anxiety Disorders | 5 | 2023 | 309 | 0.750 |
Why?
|
| Antipsychotic Agents | 5 | 2008 | 68 | 0.700 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2016 | 12 | 0.690 |
Why?
|
| Blood Pressure | 2 | 2015 | 646 | 0.650 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 123 | 0.650 |
Why?
|
| Sleep Paralysis | 2 | 2008 | 2 | 0.650 |
Why?
|
| Arousal | 2 | 2019 | 86 | 0.640 |
Why?
|
| Perception | 1 | 2019 | 195 | 0.600 |
Why?
|
| Military Personnel | 1 | 2018 | 90 | 0.600 |
Why?
|
| Residence Characteristics | 2 | 2018 | 322 | 0.600 |
Why?
|
| Darkness | 1 | 2017 | 27 | 0.580 |
Why?
|
| Hydrocortisone | 2 | 2014 | 78 | 0.580 |
Why?
|
| Period Circadian Proteins | 1 | 2016 | 37 | 0.560 |
Why?
|
| Sleep Stages | 1 | 2016 | 6 | 0.560 |
Why?
|
| Emotions | 1 | 2019 | 220 | 0.560 |
Why?
|
| Severity of Illness Index | 9 | 2016 | 610 | 0.550 |
Why?
|
| Receptors, Odorant | 1 | 2016 | 42 | 0.540 |
Why?
|
| Risperidone | 2 | 2006 | 5 | 0.520 |
Why?
|
| Combat Disorders | 2 | 2006 | 4 | 0.520 |
Why?
|
| Obesity | 2 | 2014 | 1067 | 0.520 |
Why?
|
| Research Design | 4 | 2013 | 313 | 0.510 |
Why?
|
| Theta Rhythm | 1 | 2014 | 7 | 0.480 |
Why?
|
| Hypnotics and Sedatives | 2 | 2005 | 26 | 0.470 |
Why?
|
| Risk Factors | 11 | 2016 | 3562 | 0.470 |
Why?
|
| Survivors | 2 | 2012 | 136 | 0.450 |
Why?
|
| Academies and Institutes | 1 | 2013 | 37 | 0.450 |
Why?
|
| Electrocardiography | 4 | 2018 | 156 | 0.450 |
Why?
|
| Middle Aged | 24 | 2018 | 10129 | 0.450 |
Why?
|
| Life Change Events | 6 | 2012 | 92 | 0.450 |
Why?
|
| Comorbidity | 8 | 2014 | 623 | 0.440 |
Why?
|
| Cytokines | 1 | 2017 | 602 | 0.440 |
Why?
|
| DNA Methylation | 1 | 2016 | 325 | 0.440 |
Why?
|
| Minority Health | 1 | 2013 | 88 | 0.440 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2013 | 48 | 0.440 |
Why?
|
| Cooperative Behavior | 2 | 2013 | 219 | 0.430 |
Why?
|
| Amygdala | 1 | 2013 | 114 | 0.420 |
Why?
|
| Cognition Disorders | 1 | 2014 | 233 | 0.410 |
Why?
|
| Minority Groups | 2 | 2014 | 596 | 0.410 |
Why?
|
| Weight Loss | 1 | 2013 | 131 | 0.410 |
Why?
|
| Community-Institutional Relations | 1 | 2013 | 187 | 0.400 |
Why?
|
| Time Factors | 6 | 2017 | 1742 | 0.390 |
Why?
|
| Fatigue | 1 | 2011 | 83 | 0.370 |
Why?
|
| Depressive Disorder | 3 | 2008 | 174 | 0.370 |
Why?
|
| Universities | 1 | 2013 | 442 | 0.360 |
Why?
|
| Wakefulness | 4 | 2018 | 21 | 0.350 |
Why?
|
| Sleep Deprivation | 2 | 2008 | 26 | 0.350 |
Why?
|
| Bipolar Disorder | 2 | 2007 | 43 | 0.340 |
Why?
|
| Healthcare Disparities | 2 | 2013 | 494 | 0.340 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 14 | 0.330 |
Why?
|
| Receptors, Serotonin | 1 | 2009 | 22 | 0.330 |
Why?
|
| Mental Recall | 1 | 2009 | 78 | 0.320 |
Why?
|
| Conditioning, Classical | 1 | 2009 | 61 | 0.320 |
Why?
|
| Alleles | 1 | 2009 | 321 | 0.300 |
Why?
|
| Extinction, Psychological | 1 | 2009 | 90 | 0.300 |
Why?
|
| Prevalence | 6 | 2015 | 1455 | 0.290 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 2721 | 0.290 |
Why?
|
| Health Status Disparities | 1 | 2013 | 642 | 0.290 |
Why?
|
| Sympathetic Nervous System | 3 | 2017 | 74 | 0.280 |
Why?
|
| Dyssomnias | 1 | 2006 | 2 | 0.270 |
Why?
|
| Trauma Severity Indices | 2 | 2016 | 26 | 0.270 |
Why?
|
| District of Columbia | 3 | 2014 | 71 | 0.270 |
Why?
|
| Actigraphy | 2 | 2018 | 15 | 0.270 |
Why?
|
| Double-Blind Method | 4 | 2022 | 286 | 0.270 |
Why?
|
| Stress Disorders, Traumatic, Acute | 1 | 2005 | 2 | 0.260 |
Why?
|
| Triazoles | 2 | 2022 | 86 | 0.250 |
Why?
|
| Alcoholism | 2 | 2008 | 240 | 0.250 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2004 | 25 | 0.240 |
Why?
|
| Prazosin | 2 | 2018 | 11 | 0.230 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2009 | 98 | 0.230 |
Why?
|
| Drug Prescriptions | 1 | 2003 | 41 | 0.230 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 1502 | 0.230 |
Why?
|
| Temazepam | 1 | 2002 | 1 | 0.220 |
Why?
|
| Primary Health Care | 4 | 2011 | 294 | 0.220 |
Why?
|
| Saliva | 2 | 2014 | 107 | 0.210 |
Why?
|
| Accidents, Traffic | 1 | 2002 | 42 | 0.210 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 63 | 0.210 |
Why?
|
| Azepines | 1 | 2022 | 17 | 0.210 |
Why?
|
| Psychotherapy | 4 | 2018 | 47 | 0.210 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1130 | 0.200 |
Why?
|
| Learning | 1 | 2021 | 117 | 0.190 |
Why?
|
| United States | 8 | 2018 | 4223 | 0.180 |
Why?
|
| Mental Health | 1 | 2023 | 303 | 0.180 |
Why?
|
| Dreams | 2 | 2018 | 8 | 0.180 |
Why?
|
| Anxiety | 3 | 2023 | 754 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 404 | 0.170 |
Why?
|
| Psychometrics | 3 | 2014 | 318 | 0.170 |
Why?
|
| Afghanistan | 1 | 2018 | 7 | 0.170 |
Why?
|
| Iraq | 1 | 2018 | 7 | 0.170 |
Why?
|
| Afghan Campaign 2001- | 1 | 2018 | 9 | 0.170 |
Why?
|
| Poverty | 1 | 2022 | 348 | 0.170 |
Why?
|
| Health Services Research | 2 | 2013 | 148 | 0.160 |
Why?
|
| Cognition | 1 | 2022 | 398 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2012 | 661 | 0.160 |
Why?
|
| Aged | 9 | 2013 | 6741 | 0.160 |
Why?
|
| Drug Therapy, Combination | 4 | 2008 | 227 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2010 | 1369 | 0.150 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 664 | 0.140 |
Why?
|
| Implosive Therapy | 1 | 2016 | 11 | 0.140 |
Why?
|
| Medical Records | 2 | 2007 | 41 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2013 | 88 | 0.140 |
Why?
|
| Panic Disorder | 2 | 2008 | 100 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2017 | 153 | 0.140 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 149 | 0.140 |
Why?
|
| Prognosis | 2 | 2015 | 739 | 0.130 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 64 | 0.130 |
Why?
|
| Role | 1 | 2015 | 10 | 0.130 |
Why?
|
| Adaptation, Psychological | 2 | 2016 | 385 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2013 | 2026 | 0.130 |
Why?
|
| Vietnam | 2 | 2006 | 50 | 0.130 |
Why?
|
| Violence | 1 | 2016 | 134 | 0.130 |
Why?
|
| Monitoring, Ambulatory | 1 | 2014 | 13 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 225 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2012 | 1378 | 0.130 |
Why?
|
| Age Distribution | 1 | 2015 | 225 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2015 | 215 | 0.120 |
Why?
|
| Down-Regulation | 1 | 2016 | 435 | 0.120 |
Why?
|
| Fourier Analysis | 1 | 2014 | 43 | 0.120 |
Why?
|
| Florida | 2 | 2007 | 410 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 219 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 196 | 0.120 |
Why?
|
| Models, Organizational | 1 | 2013 | 32 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2016 | 513 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 36 | 0.110 |
Why?
|
| Length of Stay | 2 | 2012 | 185 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2006 | 974 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2013 | 2379 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 259 | 0.110 |
Why?
|
| Electroencephalography | 1 | 2014 | 116 | 0.110 |
Why?
|
| Acute Disease | 2 | 2023 | 147 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2017 | 854 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2015 | 1492 | 0.110 |
Why?
|
| Waist Circumference | 1 | 2013 | 89 | 0.110 |
Why?
|
| Program Development | 1 | 2013 | 233 | 0.110 |
Why?
|
| Colonic Polyps | 1 | 2013 | 67 | 0.100 |
Why?
|
| Logistic Models | 1 | 2015 | 923 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2015 | 753 | 0.100 |
Why?
|
| Adenoma | 1 | 2013 | 89 | 0.100 |
Why?
|
| Child | 4 | 2014 | 3131 | 0.100 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 140 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2006 | 484 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1207 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 128 | 0.100 |
Why?
|
| Religion | 1 | 2012 | 87 | 0.100 |
Why?
|
| Life Style | 1 | 2013 | 308 | 0.100 |
Why?
|
| Inflammation | 1 | 2015 | 618 | 0.090 |
Why?
|
| Linear Models | 1 | 2011 | 275 | 0.090 |
Why?
|
| Cyclonic Storms | 1 | 2011 | 64 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2008 | 217 | 0.090 |
Why?
|
| Piperazines | 2 | 2008 | 111 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2012 | 187 | 0.090 |
Why?
|
| Wounds, Penetrating | 1 | 2010 | 22 | 0.090 |
Why?
|
| New Hampshire | 2 | 2007 | 5 | 0.090 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2010 | 29 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2012 | 230 | 0.090 |
Why?
|
| Dementia | 1 | 2011 | 131 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2010 | 56 | 0.090 |
Why?
|
| Models, Biological | 1 | 2013 | 677 | 0.090 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2009 | 2 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2010 | 100 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 380 | 0.090 |
Why?
|
| Generalization, Stimulus | 1 | 2009 | 1 | 0.080 |
Why?
|
| Convalescence | 1 | 2008 | 7 | 0.080 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 2008 | 2 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2010 | 126 | 0.080 |
Why?
|
| Quinolones | 1 | 2008 | 7 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2008 | 15 | 0.080 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2008 | 12 | 0.080 |
Why?
|
| Aggression | 1 | 2008 | 89 | 0.080 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2008 | 25 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 441 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2007 | 31 | 0.080 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 103 | 0.070 |
Why?
|
| Nipecotic Acids | 1 | 2007 | 2 | 0.070 |
Why?
|
| GABA Agonists | 1 | 2007 | 21 | 0.070 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2006 | 22 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2006 | 17 | 0.070 |
Why?
|
| Genotype | 1 | 2009 | 730 | 0.070 |
Why?
|
| Domestic Violence | 1 | 2006 | 30 | 0.070 |
Why?
|
| Health Surveys | 1 | 2008 | 373 | 0.070 |
Why?
|
| Age Factors | 1 | 2009 | 1033 | 0.070 |
Why?
|
| Sex Factors | 1 | 2009 | 898 | 0.070 |
Why?
|
| Registries | 1 | 2007 | 335 | 0.070 |
Why?
|
| Gene Expression | 1 | 2009 | 674 | 0.070 |
Why?
|
| Dissociative Disorders | 1 | 2005 | 10 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 628 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 50 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2008 | 451 | 0.060 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2004 | 5 | 0.060 |
Why?
|
| Sertraline | 1 | 2004 | 7 | 0.060 |
Why?
|
| Community Mental Health Centers | 1 | 2003 | 3 | 0.060 |
Why?
|
| Incidence | 3 | 2013 | 922 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2005 | 212 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 225 | 0.050 |
Why?
|
| Animals | 3 | 2015 | 15081 | 0.050 |
Why?
|
| Schizophrenic Psychology | 1 | 2002 | 17 | 0.050 |
Why?
|
| Hypertension | 1 | 2009 | 796 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 43 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 47 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2002 | 76 | 0.050 |
Why?
|
| Injury Severity Score | 2 | 2012 | 61 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 55 | 0.050 |
Why?
|
| Disease Progression | 1 | 2023 | 601 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1039 | 0.050 |
Why?
|
| Health Policy | 1 | 2002 | 165 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 730 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 562 | 0.040 |
Why?
|
| Depression | 1 | 2006 | 712 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 885 | 0.040 |
Why?
|
| Hospitalization | 1 | 2002 | 388 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 400 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2018 | 15 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 64 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2014 | 1418 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 148 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2015 | 36 | 0.030 |
Why?
|
| Women | 1 | 2012 | 27 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2012 | 13 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2012 | 19 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2012 | 80 | 0.030 |
Why?
|
| New Orleans | 1 | 2011 | 13 | 0.030 |
Why?
|
| Psychotropic Drugs | 1 | 2011 | 12 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2012 | 79 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 455 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 191 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 418 | 0.020 |
Why?
|
| Craniocerebral Trauma | 1 | 2010 | 19 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2011 | 118 | 0.020 |
Why?
|
| Benztropine | 1 | 2008 | 1 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2008 | 30 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2010 | 291 | 0.020 |
Why?
|
| Psychology | 1 | 2008 | 36 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 519 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 583 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 175 | 0.020 |
Why?
|
| Quality of Life | 1 | 2012 | 481 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2007 | 42 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 108 | 0.020 |
Why?
|
| REM Sleep Parasomnias | 1 | 2006 | 1 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 801 | 0.020 |
Why?
|
| Infant | 1 | 2010 | 1046 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2006 | 34 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2005 | 38 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 113 | 0.020 |
Why?
|
| Cause of Death | 1 | 2005 | 156 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 441 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 935 | 0.010 |
Why?
|
| Mass Screening | 1 | 2007 | 462 | 0.010 |
Why?
|
| Critical Pathways | 1 | 2002 | 15 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2002 | 29 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 128 | 0.010 |
Why?
|
| Medicaid | 1 | 2002 | 109 | 0.010 |
Why?
|